Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-450 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | ABT-450/ritonavir |
| 2 | PLACEBO_COMPARATOR | Placebo for ABT-450/placebo for ritonavir |
| Name | Type | Description |
|---|---|---|
| ABT-450 | DRUG | capsules, QD or BID, 14 days, ascending doses |
| ritonavir | DRUG | capsules, QD or BID, 14 days, ascending doses |
| Placebo for ABT-450 | DRUG | capsule, QD or BID, 14 days |
| Placebo for ritonavir | DRUG | capsule, QD or BID, 14 days |
Inclusion Criteria: * overall healthy subjects * non-childbearing potential females included Exclusion Criteria: * history of significant sensitivity to any drug * positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab * history of gastrointestinal issues or procedures * history of seizures...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
ABT-450 is an investigational small molecule developed by Abbott Laboratories for the treatment of hepatitis C virus (HCV) infection. It was studied in Phase 1 clinical trials, including pharmacokinetic, safety, and tolerability studies in healthy adult volunteers. It is not an approved medicine and remains in early clinical development.
ABT-450 was being developed as a treatment for hepatitis C virus infection. The clinical program evaluated its pharmacokinetics, safety, and tolerability when given with ritonavir in healthy adult volunteers. All reported trials were Phase 1 studies, and no later-stage efficacy trials in patients with HCV infection are listed.
ABT-450 was developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott sponsored the Phase 1 studies of the compound in the United States. The asset is an investigational small molecule for hepatitis C virus infection.
ABT-450 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with no active trials ongoing. The studies enrolled a combined total of 46 healthy adult volunteers. ABT-450 is investigational and has not been approved for any indication.
Two completed Phase 1 trials studied ABT-450: NCT00931281, which evaluated pharmacokinetics, safety, and tolerability of ABT-450 with ritonavir in 38 healthy adults, and NCT00909311, which assessed the effect of food on pharmacokinetics, safety, and tolerability in 8 healthy adults. Both were conducted in the United States.
Yes. The ABT-450 Phase 1 program was randomized, double-blind, and active-controlled. Both completed trials, NCT00931281 and NCT00909311, enrolled healthy adult volunteers of any sex, aged 18 years and older, in the United States. Combined enrollment across the two studies was 46 participants.